Forward to: Pharma Strategy

Pharmaceutical Intelligence
Workflows

Ten agent workflows for the Pharma Strategy team — automated drug pipeline monitoring, pharmaceutical competitor analysis, patent cliff tracking, market access intelligence, biosimilar threat assessment, licensing opportunity detection, manufacturing capacity analysis, launch readiness monitoring, formulary positioning intelligence, and pricing strategy benchmarking — providing comprehensive domain-level pharmaceutical competitive signals.

1Drug Pipeline Monitoring

AI agent tracks competitor drug pipelines by monitoring pharmaceutical company websites for product page updates, press releases, investor presentations, and clinical development milestones across all therapeutic areas.

1
Scan Pharma Pipeline Pages
/products /investors /press /blog IAB Categories OpenPageRank
DRUG PIPELINE SCAN — TOP 50 PHARMA COMPANIES ════════════════════════════════════════════════════════════ COMPANIES MONITORED: 50 large pharma + 890 biotech PIPELINE CHANGES DETECTED: 67 in last 30 days pfizer.com /products: 3 assets moved from Phase II to Phase III /investors: Pipeline day scheduled — March 2026 /press: New RSV vaccine pediatric indication filing /careers: 87 new R&D roles in oncology division astrazeneca.com /products: ADC platform expanded — 4 new candidates listed /investors: $2B acquisition of ADC biotech announced /press: Breakthrough therapy designations for 2 assets /blog: CMO commentary on precision medicine strategy modernatx.com /products: mRNA oncology pipeline restructured /investors: Reduced 2026 revenue guidance /careers: 12% workforce reduction announced /press: Pivoting from COVID to oncology + rare disease
2
Detect Pipeline Shifts & Trends
Pipeline Trend
ADC Platform Arms Race — 8 of top 20 pharma companies added ADC assets to /products pipeline pages in Q1 2026. AstraZeneca's $2B acquisition confirms ADC as dominant modality. Total ADC candidates across monitored domains: 147, up from 89 in Q1 2025 (+65%).
HOT SPACE — ADC pipeline growth accelerating rapidly
3
Generate Pipeline Intelligence Brief

Pipeline Intelligence Brief — Q1 2026

KEY PIPELINE MOVEMENTS ──────────────────────────────────────── Total pipeline changes: 67 | Phase advances: 23 | Terminations: 8 New candidates: 31 | Indication expansions: 5 STRATEGIC IMPLICATIONS 1. ADC competition intensifying — differentiation critical for late entrants 2. Moderna pivot creates oncology mRNA opportunity gap 3. Pfizer Phase III moves signal potential 2028 launch competition 4. AstraZeneca acquisition validates ADC platform approach 5. 8 biotech terminations create potential asset acquisition targets

2Patent Cliff & LOE Tracking

AI agent monitors pharmaceutical companies approaching patent cliffs by tracking changes to their legal pages, investor communications, lifecycle management strategies, and biosimilar competitor activity.

1
Track Patent Expiry Signals
/legal /investors /products /press Domain Ages IAB Categories
PATENT CLIFF MONITORING — 2026-2030 EXPOSURE ════════════════════════════════════════════════════════════ abbvie.com /legal: Humira patent settlement updates — 10 biosimilar entrants /investors: Humira revenue decline -42% YoY projected /products: Skyrizi/Rinvoq growth offsetting Humira LOE merck.com /legal: Keytruda patent expiry 2028 — lifecycle strategy in progress /investors: $27B annual revenue at risk from Keytruda LOE /products: Subcutaneous Keytruda formulation in development /press: 3 new indication filings to extend market exclusivity
2
Monitor Biosimilar Competition
LOE Impact
Keytruda LOE 2028 — Domain monitoring reveals 14 biosimilar developers now featuring Keytruda biosimilar programs on /products pages. Combined with Merck's subcutaneous formulation strategy on /products and 3 indication expansion filings on /press, this creates both threat and opportunity signals for the PD-1 class.
HIGH IMPACT — $27B revenue at risk, 14 biosimilar competitors detected
3
Track Lifecycle Management Strategies
LOE Strategy Evolution
2025-07-10 Merck /products added subcutaneous Keytruda formulation page
2025-09-22 6 biosimilar developer domains launched Keytruda biosimilar /products pages
2025-11-15 Merck /investors presented 5-year post-LOE strategy
2026-01-08 8 additional biosimilar programs detected — accelerating competition
2026-02-14 Merck /press filed 3 new indication supplements to extend exclusivity

3Market Access Intelligence

AI agent monitors payer, PBM, and health technology assessment body websites to track formulary decisions, reimbursement policies, HEOR requirements, and market access barriers for pharmaceutical products.

1
Monitor HTA & Payer Decisions
/docs /press /compliance /products Countries
MARKET ACCESS INTELLIGENCE — GLP-1 CLASS ════════════════════════════════════════════════════════════ nice.org.uk /docs: Draft appraisal for GLP-1 obesity indication — cost-effectiveness concerns /press: QALY threshold not met at current list price iqwig.de /docs: Additional benefit assessment — considerable benefit confirmed /press: Positive early benefit assessment for combination therapy cms.gov /docs: Proposed IRA negotiation drug list — GLP-1 class included /compliance: Medicare Part D coverage determination pending express-scripts.com /products: Preferred formulary excludes 2 GLP-1 products /press: New prior authorization requirements for obesity indication
2
Assess Market Access Barriers
Access Signal
GLP-1 Reimbursement Headwinds — NICE draft negative, CMS IRA negotiation list inclusion, and PBM formulary exclusions signal increasing access barriers. 3 of 5 major markets show negative or mixed reimbursement signals from domain monitoring. HEOR data package needs strengthening.
BARRIER — Multi-market access challenges detected
3
Generate Access Strategy Report

Market Access Strategy

ACCESS LANDSCAPE SUMMARY ──────────────────────────────────────── Markets monitored: 12 | Positive decisions: 4 | Negative/pending: 5 | Mixed: 3 RECOMMENDED ACTIONS 1. Submit NICE reappraisal with updated RWE data package 2. Prepare IRA negotiation strategy — engagement window Q2 2026 3. Negotiate PBM preferred status — outcomes-based contract model 4. Leverage IQWiG positive assessment for EU reference pricing 5. Develop obesity-specific HEOR dossier for US payer presentations

4Biosimilar Threat Assessment

AI agent monitors biosimilar developer websites to detect new program announcements, regulatory filings, manufacturing investments, and commercial launch preparations that could impact branded product revenues.

1
Scan Biosimilar Developer Activity
/products /press /investors /careers Domain Ages Countries
BIOSIMILAR THREAT SCAN — BRANDED PORTFOLIO ════════════════════════════════════════════════════════════ BIOSIMILAR DEVELOPERS MONITORED: 124 domains BRANDED ASSETS PROTECTED: 12 products sandoz.com /products: Biosimilar to our Product A — Phase III complete /press: BLA filing expected Q2 2026 /careers: 28 commercial launch roles posted — US market Countries: US, EU, Japan launch planned simultaneously biocon.com /products: Biosimilar to our Product B — Phase I/III initiated /investors: $200M manufacturing investment announced /press: Partnership with Viatris for US commercialization Domain Age: 7,890 days | PageRank: 5.2/10
2
Assess Competitive Launch Timeline
Threat Assessment
Product A Biosimilar — Sandoz — Phase III complete, BLA filing imminent. Commercial team hiring (28 roles) indicates US launch preparation. /careers roles posted in 6 US regions suggests national launch strategy. Estimated launch: Q4 2027. Revenue impact: $1.2-1.8B annually.
IMMINENT — 18-24 month window to prepare defense strategy

5Licensing & BD Opportunity Detection

AI agent identifies in-licensing and business development opportunities by monitoring biotech company websites for partnership signals, data readout announcements, funding status changes, and strategic fit indicators.

1
Detect Licensing-Ready Biotechs
/products /investors /partners /press /careers OpenPageRank
BD OPPORTUNITY DETECTION — ONCOLOGY ASSETS ════════════════════════════════════════════════════════════ HIGH-PRIORITY OPPORTUNITIES: arcusbio.com /products: Novel bispecific antibody — Phase II positive readout /investors: Cash runway 14 months — may seek partner /partners: Currently no commercial partner for lead asset /careers: Hiring freeze detected — commercial team not building SIGNAL: Phase II data + limited cash + no partner = licensing opportunity revelationbio.com /products: First-in-class target — preclinical, strong MOA data /investors: Series A only — $45M raised, insufficient for Phase II /partners: "Partnership inquiries welcome" added to page /leadership: Former big pharma R&D chief as CEO SIGNAL: Actively seeking partner, novel target, experienced team
2
Score & Prioritize Opportunities
BD Opportunity
Arcus Bio — Top Priority — Phase II positive data + 14-month cash runway + no commercial partner + hiring freeze = strong partnership motivation. Strategic fit: bispecific complements our ADC portfolio. Recommend outreach within 30 days before competitive bids emerge.
PRIORITY — Optimal timing for partnership approach

6Manufacturing & Supply Chain Intelligence

AI agent monitors CDMO, raw material supplier, and pharmaceutical manufacturer websites to track capacity expansions, quality issues, supply chain risks, and manufacturing partnership opportunities.

1
Monitor CDMO Capacity & Quality
/products /press /compliance /careers Countries
CDMO LANDSCAPE MONITORING — ADC MANUFACTURING ════════════════════════════════════════════════════════════ lonza.com /products: ADC manufacturing capacity expanded — new conjugation suite /press: $500M Swiss facility investment for biologics/ADC /compliance: FDA inspection — no Form 483 observations /careers: 42 ADC manufacturing specialist roles posted catalent.com /products: ADC capacity waitlist — 18-month lead time /compliance: FDA warning letter — Bloomington facility /press: Restructuring announcement — 3 facility closures /careers: Hiring reduced 34% vs. prior quarter
2
Assess Supply Chain Risk
Supply Risk
Catalent Warning Letter — FDA warning letter at Bloomington + restructuring + hiring reduction signals operational stress. If Catalent is current or planned CDMO, risk mitigation required. Lonza expansion provides alternative capacity but waitlist forming. Recommend dual-source strategy immediately.
RISK — CDMO quality issues + capacity constraints industry-wide

7Launch Readiness Monitoring

AI agent tracks competitor product launch preparations by monitoring commercial team hiring, payer engagement signals, marketing website deployments, and HCP education platform launches to predict and prepare for competitive entries.

1
Detect Launch Preparation Signals
/careers /products /press /events Domain Ages Personas
LAUNCH READINESS SCAN — COMPETITOR PRODUCTS ════════════════════════════════════════════════════════════ competitor-pharma.com /careers: 187 sales rep roles posted across 9 US regions /products: Branded product website launched (separate domain) /events: 8 medical education symposia scheduled Q2-Q3 2026 /press: PDUFA date confirmed — June 15, 2026 Personas: Oncologists, nurse practitioners, pharmacists New branded domain detected: product-x-hcp.com (Age: 14 days) /docs: Prescribing information draft posted /events: Speaker bureau recruitment page active ASSESSMENT: Full commercial launch preparation confirmed
2
Estimate Launch Timeline
Competitor Launch Preparation Timeline
2025-10-01 First commercial roles posted on /careers (12 MSL positions)
2025-12-15 Branded HCP domain registered — product-x-hcp.com
2026-01-08 Sales force expansion — 187 rep roles across all regions
2026-01-22 /events medical education symposia announced for Q2-Q3
2026-02-14 PDUFA date confirmed on /press — June 15, 2026 approval expected

8Pricing & Reimbursement Benchmarking

AI agent monitors pharmaceutical pricing pages, WAC announcements, patient assistance programs, and outcomes-based contracting signals across competitor and payer domains to inform optimal pricing strategy.

1
Track Competitor Pricing Signals
/pricing /products /press /support Countries
PRICING BENCHMARK — ONCOLOGY THERAPEUTICS ════════════════════════════════════════════════════════════ enhertu.com (Daiichi Sankyo/AZ) /pricing: WAC: $13,200/month — no change in 12 months /support: Copay assistance program expanded to $0 OOP padcev.com (Seagen/Astellas) /pricing: WAC increased 6.5% — January 2026 /support: Free drug program for uninsured patients launched MARKET PRICING LANDSCAPE: ADC class average WAC: $14,800/month Range: $11,500 - $18,200/month Trend: +4.2% avg increase in 2025, slowing from +7.1% in 2024
2
Generate Pricing Strategy Recommendation

Pricing Strategy Recommendation

PRICING ANALYSIS ──────────────────────────────────────── Competitors benchmarked: 14 | Class average: $14,800/month IRA impact: Negotiation eligible year 9 post-launch Patient access programs: 100% of competitors offer copay assist LAUNCH PRICE RECOMMENDATION Recommended WAC: $15,200/month (moderate premium for novel MOA) Rationale: 3% above class average justified by differentiated efficacy Patient assistance: Match competitor $0 OOP copay programs Outcomes-based contracting: Prepare for 3 major PBM negotiations

9Medical Affairs Intelligence

AI agent monitors medical education platforms, congress websites, and publication databases to track scientific exchange activities, advisory board compositions, and medical affairs competitive positioning.

1
Track Medical Education Landscape
/events /blog /docs /partners Personas
MEDICAL AFFAIRS INTELLIGENCE — ONCOLOGY ════════════════════════════════════════════════════════════ asco.org /events: 2026 Annual Meeting — 847 abstracts in our therapeutic area /docs: Updated guidelines — new treatment algorithm published /blog: Editor's picks highlight combination therapy trend nccn.org /docs: Guideline update — competitor product upgraded to Category 1 /events: Guidelines panel meeting March 2026 — our data under review esmo.org /events: Congress 2026 — abstract submission window open /docs: Clinical practice guidelines revision — ADC section expanded
2
Identify Guideline Impact
Guideline Signal
NCCN Category 1 Upgrade for Competitor — Competitor product upgraded to Category 1 recommendation based on Phase III OS data. Our product currently Category 2A. March panel meeting is critical opportunity — need updated survival data submission before deadline. ESMO ADC section expansion provides complementary positioning opportunity.
URGENT — NCCN panel meeting in 30 days, data submission required

10Global Regulatory Filing Intelligence

AI agent monitors regulatory authority websites across major markets to track filing acceptances, review timelines, advisory committee schedules, and approval decisions for competitive intelligence and regulatory strategy optimization.

1
Monitor Global Filing Activity
/press /docs /compliance /products Countries Domain Ages
GLOBAL REGULATORY FILING TRACKER ════════════════════════════════════════════════════════════ US — FDA fda.gov: 4 new ADC-class BLAs accepted for review Priority Review granted: 2 | Standard: 2 ODAC meeting scheduled: 1 (March 2026) EU — EMA ema.europa.eu: 3 MAA filings in oncology validated Accelerated assessment: 1 | Standard: 2 CHMP opinion: 2 positive opinions expected Q2 2026 JAPAN — PMDA pmda.go.jp: 2 oncology NDAs filed Priority review: 1 | Conditional approval track: 1 CHINA — NMPA nmpa.gov.cn: 5 domestic ADC filings detected Breakthrough therapy designations: 3 granted in Q1 2026
2
Assess Competitive Filing Impact
Regulatory Signal
China ADC Filing Surge — 5 domestic ADC filings at NMPA in Q1 2026 represents a 150% increase YoY. Chinese biotechs increasingly filing globally — 3 of 5 also have FDA IND applications detected via /press pages. This will compress global ADC competitive timelines by 12-18 months.
ACCELERATING — China-origin ADC competition growing rapidly
3
Generate Regulatory Strategy Brief

Global Regulatory Intelligence Brief

FILING LANDSCAPE SUMMARY ──────────────────────────────────────── Active competitor filings: 14 across 4 major markets Priority/accelerated reviews: 7 (50% of filings) Expected approvals in next 12 months: 6 STRATEGIC RECOMMENDATIONS 1. Accelerate FDA filing — 2 competitors have priority review 2. Submit EMA MAA with accelerated assessment request 3. Prepare China strategy — 5 domestic competitors advancing 4. Leverage Japan conditional approval for early market access 5. Align global filing sequence: US → EU → Japan → China
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 100M+ domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.